Journal Article

FZJ-2019-01479

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma

Werner, J.-M. ; Schweinsberg, V. ; Schroeter, M. ; von Reutern, B. ; Malter, M. P. ; Schlaak, M. ; Fink, G. R.FZJ* ; Mauch, C. ; Galldiks, N. (Corresponding author)FZJ*

2019
Frontiers Media Lausanne

This record in other databases:    

Please use a persistent id in citations: http://hdl.handle.net/2128/21649  doi:10.3389/fonc.2019.00084

Abstract: Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially with BRAF wild-type. However, several checkpoint inhibitor-related complications have been reported, including severe adverse events in the central and peripheral nervous system. In particular, in the recent past, the occurrence of myasthenia gravis following checkpoint inhibitor monotherapy, particularly nivolumab or ipilimumab, has been reported. In contrast, reports on PD-1/CTLA-4 combination blockade—usually with fatal clinical outcome—are scarce. We here report a case with combination immune checkpoint blockade-related myasthenia gravis with favorable clinical outcome.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2019

---

Database coverage:
; ; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---